Amphastar Pharma (AMPH) Misses Q4 EPS by 20c
Tweet
Share
E-mail
Get Alerts AMPH Hot Sheet
Join SI Premium – FREE
Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of $0.73, $0.20 worse than the analyst estimate of $0.93. Revenue for the quarter came in at $183.1 million versus the consensus estimate of $191.76 million.
For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
- CrowdStrike Holdings Inc. (CRWD) Tops Q1 EPS by 3c, Offers Guidance
- Five Below (FIVE) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
